CAS: 4088-84-0; 2-Fluoro-5-Trifluoromethylbenzonitrile

上下游产品

2-氟-5-三氟甲基苯甲酸 2-Fluoro-5-(Trifluoromethyl)Benzoic Acid 115029-23-7
2-氟-5-(三氟甲基)苯甲酰胺 2-Fluoro-5-Trifluoromethylbenzamide 207919-05-9

2-氟-5-(三氟甲基)苯甲酰胺置于氯化亚砜,N,N-二甲基甲酰胺体系中,化学反应生成 2-氰基-1-氟-4-(三氟甲基)苯
参考文献: Bicyclic Derivatives As Ccr2 Modulators[fr] Dérivés Bicycliques Utilisés En Tant Que Modulateurs De Ccr2
标题: Bicyclic Derivatives As Ccr2 Modulators[fr] Dérivés Bicycliques Utilisés En Tant Que Modulateurs De Ccr2
摘要:The Present Disclosure Relates Generally To Small Molecule Modulators Of Chemotactic Cytokines (Chemokine) Receptors Ccr2,Or A Pharmaceutically Acceptable Salt,Stereoisomer,Mixture Of Stereoisomers Or Prodrug Thereof,And Methods Of Making And Using Thereof.

专利信息

专利号:WO-9857638-A1
优先权日:1997-06-18
标题:ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
发明人：PATANE MICHAEL A; BOCK MARK G; NEWTON RANDALL C
权利人:MERCK & CO INC; PATANE MICHAEL A; BOCK MARK G; NEWTON RANDALL C
摘要:This invention relates to certain novel compounds and derivates thereof, their synthesis, and their use as alpha 1a adrenergic receptor antogonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

专利号:US-6376503-B1
优先权日:1997-06-18
标 题 :Alpha 1a adrenergic receptor antagonists
发明人：PATANE MICHAEL A; BOCK MARK G; NEWTON RANDALL C; LAGU BHARAT
权利人:MERCK & CO INC; SYNAPTIC PHARMA CORP
摘要:This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.